BACKGROUND: Patient-reported quality of life (QOL) after salvage brachytherapy for radiorecurrent prostate cancer has not been well-characterized prospectively. METHODS: We examined 25 men who recurred after primary radiotherapy for prostate cancer and received MRI-guided salvage brachytherapy as part of a prospective Phase II study. These patients received prospectively a validated patient-reported QOL questionnaire to fill out at baseline, as well as 3, 15, and 27 months after re-irradiation to determine the degree of sexual, bowel, and urinary dysfunction (maximum dysfunction score=100). RESULTS: On average, sexual function continued to decline with time, and patients had significantly worse sexual function scores at 27 months than baseline (p=0.01). Although bowel and urinary symptoms worsened acutely at 3 or 15 months, they showed on average some improvement by 27 months, and there were no significant differences between baseline and 27-month urinary or bowel scores. An interval to re-irradiation less than 4.5 years and prior brachytherapy were each associated significantly with the largest decrements in bowel function (p=0.035). CONCLUSION: Similar to the patterns seen in the de novo setting, patients who receive salvage brachytherapy report a worsening of bowel and urinary symptoms followed by some improvement by 27 months, while sexual function steadily declines over time. Interval to re-irradiation and type of prior radiation received may be used to counsel and optimize selection of men for salvage brachytherapy with regard to QOL endpoints.
BACKGROUND:Patient-reported quality of life (QOL) after salvage brachytherapy for radiorecurrent prostate cancer has not been well-characterized prospectively. METHODS: We examined 25 men who recurred after primary radiotherapy for prostate cancer and received MRI-guided salvage brachytherapy as part of a prospective Phase II study. These patients received prospectively a validated patient-reported QOL questionnaire to fill out at baseline, as well as 3, 15, and 27 months after re-irradiation to determine the degree of sexual, bowel, and urinary dysfunction (maximum dysfunction score=100). RESULTS: On average, sexual function continued to decline with time, and patients had significantly worse sexual function scores at 27 months than baseline (p=0.01). Although bowel and urinary symptoms worsened acutely at 3 or 15 months, they showed on average some improvement by 27 months, and there were no significant differences between baseline and 27-month urinary or bowel scores. An interval to re-irradiation less than 4.5 years and prior brachytherapy were each associated significantly with the largest decrements in bowel function (p=0.035). CONCLUSION: Similar to the patterns seen in the de novo setting, patients who receive salvage brachytherapy report a worsening of bowel and urinary symptoms followed by some improvement by 27 months, while sexual function steadily declines over time. Interval to re-irradiation and type of prior radiation received may be used to counsel and optimize selection of men for salvage brachytherapy with regard to QOL endpoints.
Authors: W U Shipley; H D Thames; H M Sandler; G E Hanks; A L Zietman; C A Perez; D A Kuban; S L Hancock; C D Smith Journal: JAMA Date: 1999-05-05 Impact factor: 56.272
Authors: Anthony V D'amico; Clare M Tempany; Delray Schultz; Robert A Cormack; Mark Hurwitz; Clair Beard; Michele Albert; Hanne Kooy; Ferenc Jolesz; Jerome P Richie Journal: Urology Date: 2003-12 Impact factor: 2.649
Authors: G L Grado; J M Collins; J S Kriegshauser; C S Balch; M M Grado; G P Swanson; T R Larson; M M Wilkes; R J Navickis Journal: Urology Date: 1999-01 Impact factor: 2.649
Authors: Daniel J Indelicato; Kenyon Meadows; Charles P Gibbs; Christopher G Morris; Mark T Scarborough; Robert A Zlotecki Journal: Int J Radiat Oncol Biol Phys Date: 2008-08-15 Impact factor: 7.038
Authors: A V D'Amico; R Cormack; C M Tempany; S Kumar; G Topulos; H M Kooy; C N Coleman Journal: Int J Radiat Oncol Biol Phys Date: 1998-10-01 Impact factor: 7.038
Authors: Nicholas G Zaorsky; Brian J Davis; Paul L Nguyen; Timothy N Showalter; Peter J Hoskin; Yasuo Yoshioka; Gerard C Morton; Eric M Horwitz Journal: Nat Rev Urol Date: 2017-06-30 Impact factor: 14.432
Authors: Juanita M Crook; Peixin Zhang; Thomas M Pisansky; Edouard J Trabulsi; Mahul B Amin; William Bice; Gerard Morton; Nadeem Pervez; Eric Vigneault; Charles Catton; Jeff Michalski; Mack Roach; David Beyer; Ashesh Jani; Eric Horwitz; Viroon Donavanik; Howard Sandler Journal: Int J Radiat Oncol Biol Phys Date: 2018-10-09 Impact factor: 7.038
Authors: Juanita Crook; Joseph P Rodgers; Thomas M Pisansky; Edouard J Trabulsi; Mahul B Amin; William Bice; Gerard Morton; Albert D Murtha; Eric Vigneault; Joelle Helou; Jeff M Michalski; Mack Roach; David Beyer; Ashesh B Jani; Eric M Horwitz; Adam Raben; Stephanie Pugh; Howard Sandler Journal: Int J Radiat Oncol Biol Phys Date: 2021-11-03 Impact factor: 7.038
Authors: Wilfred Ngwa; Rajiv Kumar; Srinivas Sridhar; Houari Korideck; Piotr Zygmanski; Robert A Cormack; Ross Berbeco; G Mike Makrigiorgos Journal: Nanomedicine (Lond) Date: 2014-05 Impact factor: 5.307
Authors: Peter Bach; Tanja Döring; Andreas Gesenberg; Cornelia Möhring; Mark Goepel Journal: Health Qual Life Outcomes Date: 2011-11-02 Impact factor: 3.186
Authors: Metha Maenhout; Marco van Vulpen; Marinus Moerland; Max Peters; Richard Meijer; Maurice van den Bosch; Paul Nguyen; Steven Frank; Jochem van der Voort van Zyp Journal: J Contemp Brachytherapy Date: 2017-04-03